Modus Therapeutics reports on preclinical data on sevuparin in CKD with anemia presented at EHA2026
Click to view quick news summary (Spoiler)
Preclinical evaluations presented at EHA2026 characterize sevuparin's dual mechanism in kidney disease, demonstrating direct anemia improvements and therapeutic synergies when combined with erythropoietin (EPO).
Modus Therapeutics Holding AB reports on preclinical data on sevuparin in chronic kidney disease (CKD) with anemia, presented at the European Hematology Association Congress 2026 (EHA2026) in Stockholm on 13 June 2026 by Dr. Michela Asperti[cite: 17].
The poster, titled “Therapeutic potential of sevuparin in chronic kidney disease anaemia: synergistic effects with EPO and molecular insights into renal protection” (PS2400), summarized preclinical data characterizing the mechanism of action of sevuparin in CKD with anemia[cite: 17]. The work was conducted in collaboration with researchers at the University of Brescia, an academic partnership that has supported Modus' preclinical and translational program since 2018[cite: 17].
Synergistic Effects and Molecular Insights
Among the observations presented, the data showed measurable effects of sevuparin on anemia in mice with CKD, both as monotherapy and in combination with EPO[cite: 17]. The poster also reported that treatment with sevuparin modified the expression of molecular markers of relevance for the pathogenesis of chronic kidney disease[cite: 17]. Together, these observations contribute to the characterization of sevuparin's mechanisms of action in this model of chronic kidney disease with anemia[cite: 17].
“The data presented at EHA2026 add valuable insights into how sevuparin may act in CKD with anemia and reinforce the biological foundation of our ongoing clinical development[cite: 17]. We look forward to building on this with a separate oral presentation at the European Iron Club Annual Meeting on 20 June 2026[cite: 17]. We are grateful to the team at the University of Brescia for their continued contribution to this program,” said John Öhd, CEO of Modus Therapeutics[cite: 17].
The data presented at EHA2026 complement the broader characterization work supporting Modus' clinical development of sevuparin in CKD with anemia, including the ongoing Phase IIa study in patients with non-dialysis CKD and anemia[cite: 17].
